An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts-Reference-Cited by-同舟云学术

An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts

Published:2017-09-28 Issue:13 Volume:130 Page:1543-1552
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Schewe Denis M.¹,Alsadeq Ameera¹,Sattler Cornelia¹,Lenk Lennart¹,Vogiatzi Fotini¹,Cario Gunnar¹,Vieth Simon¹,Valerius Thomas²,Rosskopf Sophia²,Meyersieck Fabian¹,Alten Julia¹,Schrappe Martin¹,Gramatzki Martin²,Peipp Matthias²,Kellner Christian²

Affiliation:

1. Pediatric Hematology/Oncology, Acute Lymphoblastic Leukemia—Berlin-Frankfurt-Münster Study Group and

2. Division of Stem Cell Transplantation and Immunotherapy, Department of Medicine II, Christian Albrechts University Kiel and University Hospital Schleswig-Holstein, Campus Kiel, Germany

Abstract

Key Points Fc-engineered CD19 antibody cures MRD in ∼50% of mice xenografted with ALL cells and is highly synergistic in combination with chemotherapy. Macrophages are important effector cells for this antibody in vitro and in vivo.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/130/13/1543/1402393/blood764316.pdf

Reference55 articles.

1. How I treat relapsed childhood acute lymphoblastic leukemia;Locatelli;Blood,2012

2. Treatment of infant leukemias: challenge and promise;Brown,2013

3. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia;Thomas;J Clin Oncol,2010

4. Rituximab in B-lineage adult acute lymphoblastic leukemia;Maury;N Engl J Med,2016

5. Novel antibody-based therapies for acute lymphoblastic leukemia;Hoelzer,2011

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis;Blood;2024-06-27

2. Memory-like natural killer cell and CD19-antibody based immunotherapy in combination with tyrosine-kinase inhibition of Ph(-like) acute lymphoblastic leukemia;2024-06-13

3. Enhanced potency of immunotherapy against B‐cell precursor acute lymphoblastic leukemia by combination of an Fc‐engineered CD19 antibody and CD47 blockade;HemaSphere;2024-02

4. Targeted therapy of central nervous system acute lymphoblastic leukemia with an integrin α6-targeted self-assembling proapoptotic nanopeptide;Engineering;2023-12

5. Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells;Frontiers in Immunology;2023-10-27